top of page
background 4_edited.png
SCGT 2024.png
Abstract 2.png

Abstract Submission closes on 10 JUNE 2024 (Closed)

background 9.webp
Shortlisted Abstracts for Oral Presentation

Watch these shortlisted Abstract Oral Presentation during Parallel Session 5A on Conference Day 2 - 20 July 2024 (Sat) 3.30pm - 4.30pm and vote for the Most Popular Oral Presentation by 20 July 2024 (Sat) 4.45pm

Augmented anti-tumour potency via functionalised mesenchymal stem cells for treatment of Peritoneal Carcinomatosis

by Dr Woo Jun Yung

Overexpression of a modified SerpinB9 molecule enhances allogeneic T cell persistence and tumor control by Granzyme B and Caspase inhibition

by Dr Lionel Low

A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells

by Dr Sin Wei-Xiang

Single cell profiling by RNA sequencing and flow cytometry reveals distinct properties of Epstein-Barr Virus-Specific T cells (EBVSTs) armoured with Chimeric Antigen Receptors (CARs)

by Dr Lindsay Kua

Toward biomanufacturing of tissue membrane for tissue regenerative therapy

by Dr Le Quang Bach

CRISPR screen identifies Gene 14 for advancing allogeneic CAR-T therapy

by Ms Clara Koh Kai Ting

Shortlisted Abstracts for Poster Presentation

Watch these shortlisted Abstract Poster Presentation on Conference Day 1 - 19 July 2024 (Fri) 5.30pm - 6.30pm

Novel AOF cytokines and T cell culture media formulation development in human T cell expansion

by Mr Ho Chung Yin

Auto-imaging Cytometry On the Slide (ICOS) for quality control of CAR-T products

by Dr Jia Meng

Two forms of corneal endothelial cell replacement therapy in a non-human primate model of corneal endothelial dysfunction

by Ms Belinda Tan

Validation of human corneal endothelial cells harvested for SNECi therapy

by Ms Ng Xiao Yu

First-in-class modular ribozyme-based biosensor

by Ms Tan Chermaine

Innovative artificial antigen presenting cell (aAPC) design for optimized NK cell expansion and activation

by Ms Fariza

Accepted Poster Abstracts

Visit Room L1-S3 and discuss with Abstract Presenting Authors on their research during allocated breaks or throughout the conference.

You may vote for the Most Popular Abstract by 19 July 2024 (Fri) 6.30pm.

19 Jul (Fri) 12.00pm – 12.15pm

Novel AOF cytokines and T cell culture media formulation development in human T cell expansion

by Mr Ho Chung Yin

HO2 as a therapeutic biomarker: A promising new strategy for combatting metastatic non-small cell lung cancer

by Dr Seul-Ki Mun

Accelerated CD19 CAR T-Cell manufacturing with enhanced vector transduction and reduced risk of CRS

by Dr Fazil Turabe

Advancing regenerative medicine: Human Trophoblast Stem Cells from Ectopic Tissue

by Mr Henry Chen

Two forms of corneal endothelial cell replacement therapy in a non-human primate model of corneal endothelial dysfunction

by Ms Belinda Tan

Analysing genetic variants and trinucleotide repeats in an asian multi-ethnic Fuchs endothelial corneal dystrophy cohort

by Ms Neo Jing Hui Dawn

STEM-T reprogramming platform technology to empower adoptive immunotherapy for solid tumor

by Dr Ong Li Teng

Optimizing the expansion and transduction of gd T cells from cord blood

by Ms Lim Pei Yu

First-in-class modular ribozyme-based biosensor

by Ms Chermaine Tan

Preclinical efficacy and safety of nebulized mesenchymal stem cells-derived extracellular vesicles in sub-health volunteers

by Mr Raymond Lv Pinlei

Mesenchymal stem cell therapy for Sjogren’s Syndrome: A systematic review of clinical trials

by Dr Faisal Parlindungan

Exploiting biophysical markers of CD8+ T Cell senescence to enhance CAR-T cell therapy

by Ms Jessalyn Low Hui Ying

19 Jul (Fri) 12.15pm – 12.30pm

Overcoming challenges in manufacturing of allogeneic natural killer (NK) cell therapies: What have we accomplished?

by Dr Wang Qiuxia, Chelsia

LCK knockout CAR-T Cells as a novel allogeneic platform

by Ms Previtha Dawn Sakthi Vale

PhytoChol®, a plant derived cholesterol as a direct replacement for transitioning to chemically-defined media

by Ms Kavitha Rajasekhar

End-to-end manufacturing of autologous CAR T cell therapies with the new Sefia™ cell therapy manufacturing platform

by Dr Chong Da Tan

Differentiation of hemogenic endothelia, CD34+ cells and macrophages from hiPSCs and hESCs

by Ms Lim Yee Ching

Cost-effectiveness and budget impact analyses of Axicabtagene Ciloleucel as second-line therapy in patients with large B-cell lymphoma in Singapore

by A/Prof Francesca Lim Wei Inng

A therapeutic approach targeting Twist1-p21 axis in MDA-MB-231, well-known Triple-negative breast cancer cells

by Ms Haelim Yoon

Transcriptomic signatures and functional characteristics of mesenchymal stromal cells in the MDS/MPN overlap syndromes

by Asst. Prof Than Hein

Semi-automated system for biomanufacturing of large hydrogel scaffold

by Mr Chan Weng Wan

19 Jul (Fri) 4.00pm – 4.15pm

Auto-imaging Cytometry On the Slide (ICOS) for quality control of CAR-T products

by Dr Jia Meng

Discovery of unshared TCRs recognizing LMP-derived epitopes from EBV variants

by Ms Andrea Budiman

Human iPSC-derived lung organoids as disease model to explore paracrine crosstalk in the tumour microenvironment associated with EGFR-TKI resistant NSCLC

by Ms Nalini Devi Verusingam

Non-viral, high-throughput primary immune cell transfection using high aspect-ratio nanostraws

by Mr Arun Kumar Ravi Kalaiselvi

Validation of human corneal endothelial cells harvested for SNECi therapy

by Ms Ng Xiao Yu

In-vivo base editing targeting human haematopoietic stem cells in a patient-derived humanised mouse of β-Thalassaemia Major

by Ms Nur Nazneen Yusof

A comparative study of CS10 and in-house freezing media for the cryopreservation of isolated CD34+ cells

by Ms Samantha Lim Pei Si

Feasibility of wash and formulation of mesenchymal stem cells in low-volume for intra-tumoral delivery using closed counterflow centrifugation

by Dr Soong Poh Loong

Innovative artificial antigen presenting cell (aAPC) design for optimized NK cell expansion and activation

by Ms Fariza

Mesenchymal Stem Cells protection mechanisms against glutamate-induced neuronal cell apoptosis

by Mrs Firda Asma'ul Husna

Utilizing Mesenchymal Stem Cell-Derived extracellular vesicles for cancer cytotoxicity through modulation of cancer stem cell signaling pathways

by Ms Milya Urfa Ahmad

Scalable solutions for expansion of non-virally generated CAR T cells

by Ms Trang Nguyen

19 Jul (Fri) 4.15pm – 4.30pm

Sonogenetic control of multiplexed genome regulation and base editing

by Dr Liu Pei

Cultivated corneal stromal keratocytes produce functional proteoglycans to restore corneal clarity

by Asst. Prof Andri K. Riau

Anti-ageing effect of human umbilical cord-derived mesenchymal stromal cells conditioned medium on senescent normal human dermal fibroblast

by Ms Lee Soke Sun

Producing genetically-corrected haemopoietic stem cells from Beta-Thalassemia patients’ induced pluripotent stem cells: An alternative strategy for ex-vivo gene modification

by Ms Janani Ramesh

An investigation using maternal stem cells in a non-human primate model: Intrauterine transplantation and post natal boost

by Ms Julie Su Li Yeo

BECA: Development-to-manufacturing platform for immune cell therapies

by Dr Chen Sixun

Targeting NLRP3 inflammasome and SIRT3 pathways: A potential strategy for enhancing stem cell survival in Ischemic Stroke

by Prof Syed Shadab Raza

Comparison of the immunomodulatory capability of Mesenchymal Stem Cells from umbilical cord with those from adipose tissue

by Dr Isabella Kurnia Liem

Non-viral genome editing in Hematopoietic Stem Cells (HSCs) for cell-therapy applications - From discovery to manufacturing

by Dr Soong Poh Loong

background 16.webp
SELECTION PROCESS

The Scientific Committee will evaluate all submissions and shortlist the posters for abstract poster presentation and oral presentation for each category.

Applicants will need to complete the submission form below and submit it.

The shortlisted applicants will be notified on the outcome of abstract poster and oral presentation by 14 JUNE 2024.

ELIGIBILITY

All are welcome to submit abstracts related to cell and gene therapy research. All abstract authors have an opportunity to be considered for abstract awards, as applicable. 

 

Abstract submissions are free and should be submitted before the submission deadline: 10 JUNE 2024 (Extended).

ABSTRACT SUBMISSION FORM

  • ​All applicants are required to submit the online abstract form.

  • Please note that this is a one-time submission and all information should be readily available before you proceed with the online submission. For any amendments after submission, please send in to sd.cell.therapy@singhealth.com.sg latest by 31 MAY 2024.

  • All submission must be in English.

  • Abstract’s title should be concise and indicative of the content of the abstract.

  • Details of authors should be given in accordance to descending order of contribution (from most to least).

  • Abstracts should not exceed 300 words. For the result section, it is not satisfactory to state, “The result will be discussed”.

  • The use of standard abbreviations is desirable. Place special or unusual abbreviations in brackets after the full word the first time it appears. Use numerals to indicate numbers, except to begin sentences.

  • Please ensure the submitted abstract form and poster does not contain spelling, grammatical or scientific errors. Posters will be reproduced exactly as submitted, and no proof reading will be undertaken.

  • The use of tables, graphs and other types of images is not permitted in the online abstract submission form but permitted in poster.

  • Abstracts not adhering to the above will not be considered. Abstracts' authors will need to register as a delegate and are encouraged attend all the sessions in the conference.

  • Abstracts' authors will need to register as a delegate and are encouraged to attend all the sessions in the summit.

ABSTRACT CATEGORIES
Box 1b.png

CATEGORY 1: BASIC SCIENCE & TRANSLATIONAL RESEARCH​

Includes research in the areas of science that is considered fundamental to the study and practice of medicine for e.g. anatomy, physiology, pathology, epidemiology, biochemistry etc. as well as translational research, which aims to facilitate the application of basic scientific discoveries in clinical and community settings.

 

Includes research that is conducted with human subjects or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator (or a colleague) directly interacts with human subjects.

 

 

Includes case study or research not limited to improvements in cell therapy patient experience, patient safety, clinical outcomes or transformative practices.

Box 2b.png
Box 3.png

CATEGORY 2: CLINICAL RESEARCH

CATEGORY 3: NURSING & ALLIED HEALTH

ABSTRACT AWARDS

1.   Most Popular Abstract Poster*

2.   Most Popular Oral Presentation**

 

3.   Best Abstract Poster and Oral Presentation for each category

*All posters will be displayed at the conference venue and voting by public will take place on 19 July 2024 .

**Voting by public will take place at the conference directly after the last oral presentation on 20 July 2024.

For Best Abstract Poster and Oral Presentation for each category, it will be evaluated for scientific merit by the Scientific Committee.

The award recipients will be announced during the Award Presentation Ceremony on 20 July 2024.

IMPORTANT DATES

Abstract submission closing date

10 JUNE 2024

Shortlisted applicants notified on the outcome of abstract poster and oral presentation

14 JUNE 2024

Public Voting for Poster Presentation

19 JULY 2024

Public Voting for Oral Presentation

20 JULY 2024

Announcement of All Award Winners

20 JULY 2024

PRESENTING AUTHOR'S PARTICULARS

Salutation*

Department*

Mailing Address*

Postal Code*

Contact Number* 

Full Name*

Institution*

City & State / Province*

Country*

Email*

ABSTRACT INFORMATION

Abstract Category*

Authors must select one category that best fit their abstracts. The Scientific Committee reserves the right to re-categorise an abstract.

Abstract Title*

Preferred Mode of Presentation*

Authors must select the preferred mode of presentation for their abstracts. The Scientific Committee reserves the right to change the mode of presentation.

Abstract Content*

Text length NOT to exceed 300 words. The text of the abstract should include section headings such as Background/Aim, Methods, Results and Conclusion.  The section headings should appear in bold.


Word Count: 0

Upload Poster in PDF

CO-AUTHOR(S)' INFORMATION

There is no co-author for this abstract.

Full Name*

Department*

City & State / Province*

Email*

Institution of Affiliation*

Country*

There is no co-author for this abstract.

background 9.webp

Thank you for your submission!

An acknowledgement email with your assigned Abstract ID will be sent to your email.

The committee will review all abstract submissions and inform you if your abstract is accepted by 14 JUNE 2024.

background 4.webp

Powered by

AveLIVE logo new.png
bottom of page